Cargando…

Hepatitis C Virus Infection and Dialysis: 2012 Update

Hepatitis C virus infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. Recent evidence has been accumulated showing that anti-HCV positive serologic status is significantly associated with lower survival in dialysis population;...

Descripción completa

Detalles Bibliográficos
Autor principal: Fabrizi, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045425/
https://www.ncbi.nlm.nih.gov/pubmed/24959533
http://dx.doi.org/10.5402/2013/159760
_version_ 1782319318326837248
author Fabrizi, Fabrizio
author_facet Fabrizi, Fabrizio
author_sort Fabrizi, Fabrizio
collection PubMed
description Hepatitis C virus infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. Recent evidence has been accumulated showing that anti-HCV positive serologic status is significantly associated with lower survival in dialysis population; an increased risk of liver and cardiovascular disease-related mortality compared with anti-HCV negative subjects has been found. According to a novel meta-analysis (fourteen studies including 145,608 unique patients), the adjusted RR for liver disease-related death and cardiovascular mortality was 3.82 (95% CI, 1.92; 7.61) and 1.26 (95% CI, 1.10; 1.45), respectively. It has been suggested that the decision to treat HCV in patients with chronic kidney disease be based on the potential benefits and risks of therapy, including life expectancy, candidacy for kidney transplant, and co-morbidities. According to recent guidelines, the antiviral treatment of choice in HCV-infected patients on dialysis is mono-therapy but fresh data suggest the use of modern antiviral approaches (i.e., pegylated interferon plus ribavirin). The summary estimate for sustained viral response and drop-out rate was 56% (95% CI, 28–84) and 25% (95% CI, 10–40) in a pooled analysis including 151 dialysis patients on combination antiviral therapy (conventional or pegylated interferon plus ribavirin).
format Online
Article
Text
id pubmed-4045425
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40454252014-06-23 Hepatitis C Virus Infection and Dialysis: 2012 Update Fabrizi, Fabrizio ISRN Nephrol Review Article Hepatitis C virus infection is still common among dialysis patients, but the natural history of HCV in this group is not completely understood. Recent evidence has been accumulated showing that anti-HCV positive serologic status is significantly associated with lower survival in dialysis population; an increased risk of liver and cardiovascular disease-related mortality compared with anti-HCV negative subjects has been found. According to a novel meta-analysis (fourteen studies including 145,608 unique patients), the adjusted RR for liver disease-related death and cardiovascular mortality was 3.82 (95% CI, 1.92; 7.61) and 1.26 (95% CI, 1.10; 1.45), respectively. It has been suggested that the decision to treat HCV in patients with chronic kidney disease be based on the potential benefits and risks of therapy, including life expectancy, candidacy for kidney transplant, and co-morbidities. According to recent guidelines, the antiviral treatment of choice in HCV-infected patients on dialysis is mono-therapy but fresh data suggest the use of modern antiviral approaches (i.e., pegylated interferon plus ribavirin). The summary estimate for sustained viral response and drop-out rate was 56% (95% CI, 28–84) and 25% (95% CI, 10–40) in a pooled analysis including 151 dialysis patients on combination antiviral therapy (conventional or pegylated interferon plus ribavirin). Hindawi Publishing Corporation 2012-12-17 /pmc/articles/PMC4045425/ /pubmed/24959533 http://dx.doi.org/10.5402/2013/159760 Text en Copyright © 2013 Fabrizio Fabrizi. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Fabrizi, Fabrizio
Hepatitis C Virus Infection and Dialysis: 2012 Update
title Hepatitis C Virus Infection and Dialysis: 2012 Update
title_full Hepatitis C Virus Infection and Dialysis: 2012 Update
title_fullStr Hepatitis C Virus Infection and Dialysis: 2012 Update
title_full_unstemmed Hepatitis C Virus Infection and Dialysis: 2012 Update
title_short Hepatitis C Virus Infection and Dialysis: 2012 Update
title_sort hepatitis c virus infection and dialysis: 2012 update
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045425/
https://www.ncbi.nlm.nih.gov/pubmed/24959533
http://dx.doi.org/10.5402/2013/159760
work_keys_str_mv AT fabrizifabrizio hepatitiscvirusinfectionanddialysis2012update